Breaking the Million-Dollar Price Barrier: Customized Immune Cell Culture Solutions Unlock Cost Reduction and Efficiency Gains

Scan the code to make an appointment right away:

Recently, the cell therapy field has been making continuous efforts to reduce prices and improve accessibility. In December 2025, five marketed CAR-T cell therapy productsFirst Officially Included in the Commercial Insurance Innovative Drug Directory, combined with the reimbursement from commercial insurances such as惠民保 (HuiMinBao), the out-of-pocket expenses for patients are expected to decrease significantly.

In addition to efforts in the payment sector, innovations are also being optimized in the R&D sector. For instance, HuaDao CAR-Tcell has disclosed that it has submitted an application for market approval to the CDE for its first CAR-T cell drug targeting refractory and relapsed non-Hodgkin lymphoma.(An application has been made for a pre-listing application communication meeting), and based on its independently developed production systems and equipment, production capacity has increasedThis candidate product may have its price reduced to around 200,000 yuan., which is expected to break the "million" pricing bottleneck. A truly patient-friendly "Chinese solution" is accelerating its implementation.

In addition, different cell types can also break accessibility limitations from the ground up, such as NK cell therapy, which can be produced on a large scale.Advantages of Spot Type, which can significantly reduce costs. Currently, most NK cell therapies are in the preclinical and clinical development stages, with promising future potential.

Whether it is the cost breakthrough of CAR-T, the off-the-shelf advantage of NK cells, or the advancements in other cell therapies, translating these potentials into widely accessible clinical treatments...All of these are inseparable from the core support of in vitro cell culture.In vitro, cells cannot obtain complex nutrients as they do in vivo, so the culture medium needs to accurately simulate the physiological environment, containing various key components to support cell growth.

Immune cells themselves have significant diversity and specificity,Each type of cell has its own specific metabolic requirements, activation pathways, and cytokine dependencies.Traditional culture media consist of fixed components and ratios, unable to provide a precisely tailored growth environment for different cell subpopulations. A "one-size-fits-all" approach to culture media may lead to issues during the cultivation process.Imbalance of nutrients leads to slow cell growth and insufficient activity., while the absence of key cytokines can affect the functional maturation of cells, making it difficult to achieve efficient enrichment and high-quality expansion of target cells. Additionally, when researchers switch cell types, they often spend a significant amount of time optimizing culture formulations, which not only slows down the research progress but also adds extra costs.

How to break this dilemma?Customizable, highly specific culture media have become critical.. This medium can be composed of a universal basal medium and customized and optimized supplements.Through this "basic + customized" flexible model, it ensures the basic nutritional supply required for cell growth while precisely matching the specific needs of different immune cell subpopulations.When this culture system is applied to the separate cultivation of T cells, NK cells, and γδT cells, it will increase the cell expansion fold by thousands of times and significantly enhance purity.

For the field of immune cell therapy, mastering efficient cell culture technology is like holding the "golden key" to therapy development and cost control. But how to precisely match the culture requirements of different cell subpopulations? How to optimize key components such as nutrients and cytokines in the culture medium formulation? How to enhance the expansion efficiency and purity of NK, T, and γδT cells through culture processes?

December 24, 2025 (Wednesday) 15:00-16:00, Yima Guest UnitedACROBiosystemsSpecial Planning"Efficient Expansion Code: Analysis of Immune Cell Culture Process Technology"Thematic Live Class.Dr. Chen Yu, Senior Product Manager of ACROBiosystemsWe will share valuable insights on precise empowerment of immune cell culture through exclusive formulations, switching of cell types and optimization of culture media, as well as cultivation data of different cells. Everyone is sincerely invited to scan the code and watch, and engage in discussions!

【Medical Innovation Classroom】Live Broadcast Registration Entrance: